BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37922690)

  • 21. An open-label, multicentre safety study of vemurafenib in patients with BRAF
    Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
    Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabrafenib and trametinib administration in patients with
    Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
    EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
    Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
    J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vemurafenib in Chinese patients with BRAF
    Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
    BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-Cancer Efficacy of Vemurafenib in
    Subbiah V; Puzanov I; Blay JY; Chau I; Lockhart AC; Raje NS; Wolf J; Baselga J; Meric-Bernstam F; Roszik J; Diamond EL; Riely GJ; Sherman EJ; Riehl T; Pitcher B; Hyman DM
    Cancer Discov; 2020 May; 10(5):657-663. PubMed ID: 32029534
    [No Abstract]   [Full Text] [Related]  

  • 28. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
    Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
    Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
    Sharma A; Shah SR; Illum H; Dowell J
    Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With
    Subbiah V; Gervais R; Riely G; Hollebecque A; Blay JY; Felip E; Schuler M; Gonçalves A; Italiano A; Keedy V; Chau I; Puzanov I; Raje NS; Meric-Bernstam F; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
    Kähler KC; Debus D; Schley G; Göppner D; Hassel JC; Meier F; Terheyden P; Stadler R; Tüting T; Kaatz M; Hoff NP; Masoudi E; Zdanowicz-Specht A; Nguyen MT; Mohr P
    Melanoma Res; 2024 Feb; 34(1):44-53. PubMed ID: 37962220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
    Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF
    Ascierto PA; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Zhukova N; Schachter J; Yan Y; Caro I; Hertig C; Xue C; Kusters L; McArthur GA; Gutzmer R
    Lancet Oncol; 2023 Jan; 24(1):33-44. PubMed ID: 36460017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
    Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
    Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
    Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH
    J Immunother Cancer; 2018 Jul; 6(1):76. PubMed ID: 30053905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
    Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
    Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.